指南与共识治疗药物监测与药物基因组学药物相互作用

澳大利亚可操作药物基因组学药物的患者暴露洞察:基于新国家指南的分析

Insights Into Patient-Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline.
指南 / 共识 · Clin Pharmacol Ther · 2025-07-18

成人(14.91%)和老年人(14.44%)的PGx药物使用率最高,儿童为3.53%。

要点

  • 成人PGx药物使用率14.91%,老年人14.44%,儿童3.53%。
  • 高达18.58%使用氯吡格雷或伏立康唑者可能因慢代谢需换药。

核心结论

  • 将PGx检测纳入常规实践具有临床潜力,尤其针对国际药物基因组学指南收录的药物。
  • 实施PGx检测前期成本显著,但可提高用药安全性和有效性及医疗成本效率。

研究设计与样本

  • 计算儿童(0-17岁)、成人(18-64岁)和老年人(65岁以上)的 incident 处方率。
  • 估算PGx检测成本(假设50%和75%人群接受度)并基于文献报道的祖先表型频率预测处方变化。

主要发现

  • 成人(14.91%)和老年人(14.44%)的PGx药物使用率最高,儿童为3.53%。
  • 常用药物包括质子泵抑制剂,所有年龄组中频繁关联CYP2C19等基因。
  • 基于祖先表型频率预测,高达18.58%使用氯吡格雷或伏立康唑的个体可能因慢代谢需要替代治疗。

临床怎么用

  • 临床可参考RCPA指南列出的35种PGx药物,关注CYP2C19等基因关联药物(如质子泵抑制剂)的检测。
  • 对使用氯吡格雷或伏立康唑的患者,可考虑PGx检测以识别慢代谢者并调整治疗。

局限性

  • 研究基于行政索赔数据,可能未完全反映实际用药和临床结局。
  • 预测处方变化依赖于文献报道的祖先表型频率,可能存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes. Using administrative claims data from the Pharmaceutical Benefits Scheme, accessed via the Australian Bureau of Statistics DataLab, we identified individuals who received any of the 35 medications between January 2021 and December 2023. Incident prescribing rates were calculated for children (0-17), adults (18-64), and older adults (65+). Adults (14.91%) and older adults (14.44%) had the highest rates of PGx medication use, followed by children (3.53%). Commonly prescribed medications included proton pump inhibitors, with frequent associations to genes such as CYP2C19 across all age groups. Estimated costs of PGx testing, assuming 50% and 75% population uptake, were highest for older adults: AUD$1.95 million and AUD$2.93 million, respectively. Predicted prescribing changes, based on literature-reported phenotype frequencies by ancestry, suggested that up to 18.58% of individuals using drugs like clopidogrel or voriconazole may need alternative treatments due to poor metabolism. These findings highlight the clinical potential of integrating PGx testing into routine practice, especially for medications included in international pharmacogenomic guidelines. While implementation would entail significant upfront costs, PGx testing could enhance medication safety and effectiveness and health care cost-efficiency. Future research should focus on scalable strategies for PGx implementation across diverse health care settings to optimize patient care globally.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ianni BD, Yiu CH, Ali MA, et al. Insights Into Patient-Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline. Clin Pharmacol Ther. 2025. PMID: 40678859. doi:10.1002/cpt.70006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。